SGRY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SGRY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Surgery Partners's enterprise value is $6,949 Mil. Surgery Partners's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $473 Mil. Therefore, Surgery Partners's EV-to-EBITDA for today is 14.68.
The historical rank and industry rank for Surgery Partners's EV-to-EBITDA or its related term are showing as below:
During the past 12 years, the highest EV-to-EBITDA of Surgery Partners was 45.89. The lowest was 11.27. And the median was 20.76.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-10-31), Surgery Partners's stock price is $28.80. Surgery Partners's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.270. Therefore, Surgery Partners's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
The historical data trend for Surgery Partners's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgery Partners Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | 16.09 | 21.06 | 22.16 | 16.18 | 18.58 |
Surgery Partners Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | 22.52 | 17.73 | 18.58 | 17.15 | 16.70 |
For the Medical Care Facilities subindustry, Surgery Partners's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Surgery Partners's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Surgery Partners's EV-to-EBITDA falls into.
Surgery Partners's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 6949.130 | / | 473.3 | |
= | 14.68 |
Surgery Partners's current Enterprise Value is $6,949 Mil.
Surgery Partners's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $473 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgery Partners (NAS:SGRY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Surgery Partners's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 28.80 | / | -0.270 | |
= | At Loss |
Surgery Partners's share price for today is $28.80.
Surgery Partners's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Surgery Partners's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Harrison R. Bane | officer: American Group President | 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027 |
Danielle Burkhalter | officer: Chief Human Resources Officer | 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027 |
Bradley R. Owens | officer: National Group President | 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027 |
David T Doherty | officer: Chief Financial Officer | 310 SEVEN SPRINGS WAY, BRENTWOOD TN 37027 |
Jason Eric Evans | officer: EVP & Chief Operating Officer | 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027 |
Anthony Taparo | officer: President, Atlantic Group | 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027 |
Jennifer Baldock | officer: Sr. VP, Gen Couns. & Sec. | 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027 |
Marissa Brittenham | officer: Chief Strategy Officer | 310 SEVEN SPRINGS WAY, BRENTWOOD TN 37027 |
Bain Capital Investors Llc | director, 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
T. Devin O'reilly | director, 10 percent owner | C/O BAIN CAPITAL PRIVATE EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02149 |
Blair E Hendrix | director, 10 percent owner | |
Andrew T. Kaplan | director | C/O BAIN CAPITAL PRIVATE EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02116 |
Wayne S Deveydt | director, officer: Chief Executive Officer | 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
Bain Capital Partners Xi, L.p. | director, 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Bain Capital Fund Xi, L.p. | director, 10 percent owner | JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116 |
From GuruFocus
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-28-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-26-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 05-07-2024
By GuruFocus Research • 03-13-2024
By GuruFocus Research • 06-04-2024
By Marketwired • 04-18-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.